Patents by Inventor Sebastian Pawlak

Sebastian Pawlak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anticancer fusion protein comprising TRAIL and interferon
    Patent number: 9161991
    Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: October 20, 2015
    Assignee: ADAMED sp. z o. o.
    Inventors: Jerzy Szczepan Pieczykolan, Krzysztof Kazimierz Lemke, Sebastian Pawlak, Bartłomiej Żerek
  • Anticancer fusion protein comprising trail
    Patent number: 9102759
    Abstract: The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: August 11, 2015
    Assignee: ADAMED SP. Z O.O.
    Inventors: Jerzy Szczepan Pieczykolan, Sebastian Pawlak, Bartlomiej Zerek, Krzysztof Kazimierz Lemke
  • ANTICANCER FUSION PROTEIN
    Publication number: 20150044162
    Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and domain (b) which is a sequence of an effector peptide inhibiting protein synthesis, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
    Type: Application
    Filed: November 28, 2012
    Publication date: February 12, 2015
    Inventors: Jerzy Szczepan Pieczykolan, Sebastian Pawlak, Michal Szymanik, Anna Maria Pieczykolan, Bartlomiej Maciej Zerek, Piotr Rózga, Albert Robert Jaworski, Malgorzata Izabela Teska-Kaminska
  • ANTICANCER FUSION PROTEIN
    Publication number: 20130251676
    Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
    Type: Application
    Filed: December 5, 2011
    Publication date: September 26, 2013
    Applicant: ADAMED SP. Z O.O.
    Inventors: Jerzy Szczepan Pieczykolan, Krzysztof Kazimierz Lemke, Sebastian Pawlak, Bartlomiej Zerek
  • ANTICANCER FUSION PROTEIN
    Publication number: 20130164254
    Abstract: The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases.
    Type: Application
    Filed: June 24, 2011
    Publication date: June 27, 2013
    Applicant: ADAMED SP. Z O.O.
    Inventors: Jerzy Szczepan Pieczykolan, Sebastian Pawlak, Bartlomiej Zerek, Krzysztof Kazimierz Lemke